HealthQuill Merck
he US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria that cause invasive pneumococcal disease.
Drugs Health Pharma

Merck’s vaccine for pneumococcal disease gets FDA’s green light

The US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria.

Read More
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or melanoma.
Drugs Health Pharma

Moderna, Merck’s skin cancer vaccine shows rise in survival rates

Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Medical Pharma

Merck discontinues trial for combo cancer drug for melanoma

HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Health Pharma

Merck’s end-stage trials of endometrial cancer therapy fail to meet goals

HQ Team May 9, 2024: Merck announced that its Phase 3 trial evaluating Keytruda therapy in combination with chemotherapy, with or without radiotherapy,.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Medical Pharma

Merck’s Keytruda receives FDA nod for cervical cancer treatment

HQ Team January 13, 2024: The U.S. Food and Drug Administration (FDA) has granted approval for the expanded use of Merck & Co’s.

Read More
Drugs Medical Pharma

Moderna’s melanoma vaccine shows promise in clinical trials

HQ Team December 23, 2023: Moderna unveiled a skin cancer vaccine that demonstrated promising results in recent clinical trials. The vaccine, administered in.

Read More
Merck announced it has got USFDA approval for its belzutifan drug, branded as Welireg, to treat an advanced form of kidney cancer.
Drugs Health Pharma

USFDA green lights Merck’s drug to treat advanced kidney cancer 

HQ Team December 15, 2023: Merck announced it got USFDA approval for its belzutifan drug, branded as Welireg, to treat an advanced form.

Read More
Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by the FDA.
Drugs Health Pharma

Merck gets priority review nod from USFDA for hypertension drug 

HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.

Read More
Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to evaluate the combination of the company's breast cancer vaccine with Merck’s Keytruda (pembrolizumab) immunotherapy.
Drugs Health Pharma

Anixa to conduct breast cancer trials with Merck’s Keytruda therapy

HQ Team August 7, 2023: Anixa Biosciences, Inc., announced that its partner Cleveland Clinic has begun enrolling subjects in a treatment arm to.

Read More
US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from eventual revenue loss as patents on its cancer immunotherapy Keytruda expires by the end of the decade.
Drugs Pharma

Merck to acquire Prometheus for $10.8 billion to step up immunology presence

HQ Team April 17, 2023: US-based Merck will buy Prometheus Biosciences for about 10.8 billion to shore up its immunology portfolio to shield itself from.

Read More